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The Lantibiotic NAI-107 Efficiently Rescues Drosophila melanogaster
from Infection with Methicillin-Resistant Staphylococcus aureus
USA300
Thomas T. Thomsen,a Biljana Mojsoska,b João C. S. Cruz,c Stefano Donadio,c,d Håvard Jenssen,b Anders Løbner-Olesen,a
Kim Rewitza
Department of Biology, University of Copenhagen, Copenhagen, Denmarka; Department of Science, Systems and Models, Roskilde University, Roskilde, Denmarkb;
Ktedogen, Milan, Italyc; Naicons Srl, Milan, Italyd
We used the fruit flyDrosophila melanogaster as a cost-effective in vivomodel to evaluate the efficacy of novel antibacterial pep-
tides and peptoids for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. A panel of peptides with
known antibacterial activity in vitro and/or in vivo was tested inDrosophila. Although most peptides and peptoids that were
effective in vitro failed to rescue lethal effects of S. aureus infections in vivo, we found that two lantibiotics, nisin and NAI-107,
rescued adult flies from fatal infections. Furthermore, NAI-107 rescuedmortality of infection with theMRSA strain USA300
with an efficacy equivalent to that of vancomycin, a widely applied antibiotic for the treatment of serious MRSA infections.
These results establishDrosophila as a useful model for in vivo drug evaluation of antibacterial peptides.
Since the golden era of antibiotic drug development of the1940s to 1960s, the development and spread of multidrug re-
sistance (MDR) have become a huge burden to societies. At pres-
ent, resistance to almost all known antibiotics has emerged with
the sequential introduction of new or improved antibiotics in
clinical and agricultural settings (1, 2). Therefore, continued de-
velopment of new or improved antibiotics is of great importance
to human health. However, new antibiotics are lacking, and few
are under development for treatment of MDR infectious bacteria,
as drug development is costly and success from in vitro discovery
to application in clinical settings is limited.
Bacterial infections with methicillin-resistant Staphylococcus
aureus (MRSA) are no longer sporadic in their distribution and
prevalence (3, 4). MRSA strains are associated with both commu-
nity (CA-MRSA)- and hospital (HA-MRSA)-acquired infections,
with the highly -lactam-resistant CA-MRSA clone USA300 ac-
counting for up to 80%of allMRSA infections in theUnited States
(5). High-level -lactam resistance is due to acquisition of staph-
ylococcal cassette chromosome mec (SCCmec) elements, includ-
ing the mecA gene, which encodes an alternative version of the
penicillin binding protein (PBP2A) that is inducible (6, 7) and has
a lowered affinity for -lactam antibiotics (8). SCCmec elements
are often associated with carriage of genes encoding products in-
volved in resistance to other antibiotics, including aminoglyco-
side-modifying enzymes, such as acetyltransferase, adenylyltrans-
ferase, or phosphotransferase (9). Due to this resistance, MRSA
treatment often includes glycopeptide antibiotics, such as vanco-
mycin, or oxazolidinones, such as linezolid. However, failure of
vancomycin treatment has been reported for vancomycin-inter-
mediate S. aureus (VISA) (10) and vancomycin-resistant S. aureus
(VRSA) (11) strains. On the other hand, linezolid resistance is rare
(12) but has been observed in association with mutations in the
rRNA gene encoding the 23S RNA or through carriage of a Cfr
rRNAmethyltransferase gene (13, 14). Furthermore, resistance to
the last-resort antibiotic daptomycin has been reported (15, 16).
Given the increasing frequency of resistance to these antibiotics, it
is important to develop improved or novel therapeutics and to
consider new strategies to contain the spread of the growing resis-
tance problem.
Peptide-based antibiotics have been proposed as the next genera-
tion of antibacterial compounds because of their widespread distri-
bution in nature as part of innate immunity. These molecules are
often amphipathic and interact with the bacterial membrane to dis-
rupt its function. The cationic peptide colistin, a bacteriocin cur-
rently used for treatment of highly resistant Gram-negative infec-
tions, is part of the polymyxins that are derived from natural
producers, such as Paenibacillus polymyxa (17). Another bacteri-
ocin, nisin, has for decades been used in the food industry against
harmful bacteria, such as S. aureus, Listeria monocytogenes, and
Clostridium botulinum (18). Nisin belongs to a subgroup known
as lantibiotics, named so for containing uncommon amino acids,
such as lanthionine, methyllanthionine, didehydroalanine, or di-
dehydroaminobutyric acid (19). Nisin has been described to dis-
rupt membrane integrity through a dual mode of action, with
inhibition of cell wall synthesis by binding to the cell wall precur-
sor lipid II and subsequent pore formation (20–22), although new
evidence points toward a more complex mechanism that includes
aggregation of lipid II (23). Peptides may be used directly as anti-
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bacterials or can serve as templates for development of small-
molecule mimetics, such as peptoids, which can accommodate
improvements to toxicity and are intrinsically less prone to deg-
radation by proteases (24).
The gap from in vitro drug screening to the large-scale efficacy
testing necessary for clinical development is hampered by the ex-
pensive, labor-intensive, and highly regulated mammalian infec-
tion models. It is therefore of interest to develop improved, cost-
effective methods with high predictive value for screening of
antibacterial compounds before these are tested in mammalian
models. Although the fruit fly Drosophila melanogaster has been
used in drug discovery (25, 26), its application for screening of
antibacterial compounds has been limited (27–29).Drosophila is a
powerful genetic model for studying disease mechanisms, and
during the past decades, it has been used extensively in elucidating
the mechanisms of innate immunity, leading to the discovery of
the conserved role of the Toll receptors (30) and the immune
deficiency (IMD) pathway (31). Studies of innate immunity in
Drosophila have sprouted the development of variousmethods for
infecting flies with important human pathogens (28, 32–34). In
the present study, we evaluated the therapeutic potential of anti-
bacterial peptides and peptoids in vivo by testing their efficacy in a
Drosophilamodel of infectionwith S. aureus 8325-4 (35) orMRSA
USA300 (36). Tests were performed with a range of different pep-
tides, including the lantibiotics nisin A (nisin) (37) and NAI-107
(38, 39), a compound that is currently undergoing preclinical
studies. Lantibiotics are usually produced by Gram-positive bac-
teria and are characterized as ribosomally synthesized peptides
containing posttranslationally created ring structures introduced
through a thioether containing lanthionine and methyllanthio-
nine residues (40). Furthermore, the following panel of synthe-
sized amphipathic cationic peptides previously shown to have
good in vitro and/or in vivo efficacy were tested: GN-2 and -4 (41,
42), HHC-9 (43), HHC-36 (44), and the peptoids GN-2 Npm9,
GN-2Ntrp5–8, andGN-4 (45).We found thatNAI-107 rescued an
otherwise lethal infection with MRSA USA300 with an efficacy
equivalent to that of vancomycin inDrosophila. Our findings also
show that treatment with nisin extends life expectancy in animals
infected with MRSA USA300, while the majority of the peptides
and peptoids tested showed no protection from infection or had
detrimental effects on the survival of the host.
MATERIALS AND METHODS
Bacteria and growth media. S. aureus strains 8325-4 (35) and USA300
(36) were used as indicated for the individual experiments. Bacterial cul-
tures were grown in cation-adjusted Mueller-Hinton broth (MHB-II) at
the indicated temperature.
Growth rates and determination of bacterial loads.The growth rates
of S. aureus strainswere examined at 37°C in vitro to determine the growth
period required to obtain balanced cultures, here defined as cultures
grown exponentially for no fewer than 6 generations. Prior to injection of
bacteria into the in vivo fly model, the inoculums were prepared as bal-
anced cultures grown at 37°C. Since flies used for in vivo infections were
kept at 29°C, the bacterial in vitro generation time was also determined at
this temperature. In vitro growth rates were defined for growth inMHB-II
by measurements of the optical density at 600 nm (OD600) at 10-min
intervals. Furthermore, we determined the in vivo generation time based
on CFU per animal by counting the CFU at various time points by ho-
mogenizing flies infected with bacteria and plating the homogenates on
mannitol salt agar (MSA). This was performed in triplicate experiments; 3
individual flies were crushed in phosphate-buffered saline (PBS), and
10 dilution series were prepared, fromwhich 10l each was spot plated
onMSA in triplicate. Themean value for each experimentwas determined
as the number of CFU per fly and plotted. However, for determination of
bacterial titers posttreatment, four replicative experiments with 40 flies
each were performed, with 8 live individual flies homogenized at each
time point. This homogenate was diluted in 1 ml PBS, and dilutions were
plated as 100-l aliquots on MSA at 0, 3, 12, and 24 h. It should be noted
that the concentration of drug inside eachflywas based onmultiples of the
MIC in 0.5l fly liquid content (described in the next section). Therefore,
it was not necessary to furtherwash the homogenate, as the drug inside the
fly could be estimated to be diluted approximately 1:2,000. Finally, initial
trials showed that washing of the homogenate provided lower CFU titers
than those obtained with unwashed samples. It should also be noted that
drug treatmentwas performed at 3 h postinfection and that the number of
CFU per fly for this time point was determined prior to treatment.
MIC testing.MICs of all tested compounds were determined accord-
ing to protocols using brothmicrodilutionmethodology (46), withminor
modifications. S. aureus was grown in 10 ml MHB-II overnight at 37°C
with shaking and then diluted 1:100 in fresh MHB-II and grown to an
OD600 of 0.2 to 0.4. Cultures were then diluted 1:10 and grown to an
OD600 of 0.2 to 0.4. These steps were performed to ensure balanced expo-
nentially growing cultures as explained above. Finally, cultures were di-
luted to 1 106 CFU ml1 and further diluted 1:1 in microtiter plates in
MHB-II with drug, leading to a final inoculum of 5  105 CFU ml1.
MICswere determined in triplicate, and ifmore than one valuewas found,
the highest was set as the MIC to keep the calculations conservative.
Injection assay. Injection assays were performed as previously de-
scribed (33) by using a Nanoject-II microinjecter, but with minor modi-
fications in the preparation of bacterial inoculums to obtain balanced
cultures, as explained above. Flies were reared on standard Bloomington
formulation at 25°C under a 12-h–12-h light-dark cycle and constant
humidity. Adult Oregon R male flies (4 to 7 days old) were used for all
injection experiments. Initial experiments with strain 8325-4 were per-
formed in duplicate, with groups of 25 to 30 animals in each experiment.
For USA300, experiments were performed in triplicate, except for the
nisin experiment, which was done only in duplicate. The inoculum was
prepared by resuspending cells in 10 mM MgSO4 vehicle (VEH) to an
OD600 of 0.06 and was kept on ice, giving an inoculum dose of 100 to 450
CFU (8325-4) or 200 to 700 CFU (USA300) in the flies after injection of
18.4 nl. Bacterial and VEH injections were administered in the soft tissue
surrounding the front legs, and drug treatment was administered in the
lower thorax at 3 h postinfection. After injection of bacteria, flies were
kept at 29°C and monitored for 48 to 96 h to determine mortality. Drug
delivery was performed at the concentrations indicated for individual
experiments. Flies which died within 3 h postinjection were considered to
have died from handling and were disregarded. It is important that when
drug concentrations were calculated, we performed a rough approxima-
tion of the fluid content of a fly. Fly fluid content was measured by drying
out 10 groups of 50 flies each and comparing dry weight to wet weight.
This resulted in an average fluid content of 0.58 l per adult male fly. For
simplicity and because we assumed that the compounds would not be
distributed to all fluids, we used 0.5l fluid as ourmeasure for calculating
drug concentrations in the flies. Further, we assumed a rapid distribution
of the compound in the open circulatory system ofDrosophila and a slow
clearance of the compounds byMalpighian tubules. Therefore, drug con-
centrations are given as the highest concentrations obtained, in multiples
of the MIC.
Statistics and graphical plots. Plotting of data was performed using
GraphPad Prism 5. All in vivo survival plots were created using Kaplan-
Meier analysis of pooled data for repetitive experiments. Statistical anal-
ysis was carried out with the log rank (Mantel-Cox) test for comparison of
survival curves. Experiments with P values of0.05were considered to be
significant and are stated in Results. Statistical analysis was performed on
the counts of CFU per fly for the different treatment groups by using
one-way analysis of variance (ANOVA) (Kruskal-Wallis test) withDunn’s
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multiple-comparison test for comparison of individual groups. Relevant
statistical results are stated in Results.
RNA preparation and qPCR. Isolation of total RNA for quantitative
PCR (qPCR) was performed by use of an RNeasy minikit (Qiagen) ac-
cording to the manufacturer’s instructions. Biological samples were col-
lected as 10 adult male flies pooled for each replicate and time point. To
reduce contamination with genomic DNA, all samples were treated on-
column with DNase. Total RNA concentrations were measured on a Qu-
bit 3.0 fluorometer, and equivalent amounts of total RNA were used for
cDNA synthesis for each sample. cDNA synthesis was performed using a
SuperScript III first-strand synthesis kit (Invitrogen) according to the
manufacturer’s instructions. qPCRwas performed on anMx3000P qPCR
system (Agilent Technologies) using the following program: 95°C for 10
min followed by 45 cycles of 95°C for 15 s, 60°C for 15 s, and 72°C for 15 s.
Dissociation curve analysis was applied to all reactions. Primers are de-
scribed in Table S1 in the supplemental material. We used Rpl23 as a
housekeeping gene to normalize expression as previously described (47).
Compounds. Ampicillin sodium salt (99%; Roth) was used as a con-
trol for efficacy in in vitro and in vivo experiments. Vancomycin was ac-
quired fromHospira as vancomycin hydrochloride for intravenous treat-
ment. The peptides GN-2, GN-4, HHC-9, and HHC-36 (all amidated at
the C terminus), nisin A (nisin), and peptoids were above 95% purity and
were synthesized and/or purified by Håvard Jenssen, Roskilde University,
Denmark. NAI-107 is a complex of congeners produced byMicrobispora
sp. 107891 and was prepared as previously described (48). The distribu-
tion of congeners for the batch used in the current study was as follows:
A1 A2 80.8%, F1 F2 9.4%, and B1 B2 4%.
RESULTS
Determination of growth of S. aureus in vitro and in vivo in a
Drosophila infection model. We determined the growth rates of
S. aureus strain 8325-4 and MRSA strain USA300 in MHB-II me-
dium at 29°C because all successive in vivo experiments were per-
formed at this temperature. Strain 8325-4 had a generation time of
57 min, while USA300 had a generation time of 44 min (data not
shown). The in vivo growth rates of the same strains were deter-
mined by injection of bacteria into flies at time zero, with samples
collected at time zero and at 3, 4 to 6, and 12 h postinfection.
USA300 had a generation time of 54 min, whereas 8325-4 had a
generation time of 104 min in vivo (Fig. 1A). Drosophila flies in-
fected with USA300 died rapidly, with no surviving flies at 24 h
postinfection (Fig. 1B). Flies infected with approximately the
same number of 8325-4 organisms lived significantly longer. We
suggest that this difference in viability reflects the difference in
in vivo growth rates of USA300 and 8325-4 bacteria.
MICs of antibacterial peptides and peptoids.We determined
the MICs of peptides and peptoids for the two strains (Table 1).
The MIC values of the amphipathic cationic peptides GN-2,
GN-4, HHC-9, andHHC-36 and the lantibiotic nisin for S. aureus
8325-4 were in the range of 4 to 10 g ml1, while those of the
GN-2 and GN-4 peptoids were higher (16 to 64 g ml1). On the
other hand, the MIC of NAI-107 against strain 8325-4 was only
0.06 g ml1, showing that NAI-107 is highly efficient at inhibit-
ing in vitro growth of S. aureus. TheMIC of NAI-107 for S. aureus
8325-4was comparable to that of ampicillin (0.01gml1). For S.
aureusUSA300, the MIC was 0.25 g ml1 for NAI-107 and 2 g
ml1 for vancomycin.
Identification of nisin andNAI-107 as efficacious treatments
for systemic S. aureus infections in aDrosophila in vivomodel.
To evaluate the therapeutic potential of the peptides and peptoids,
we determined their ability to rescue flies with an otherwise lethal
systemic S. aureus 8325-4 infection. In order to establish the ap-
propriate dosages, we used the following reasoning. Because in-
sects are known to have an open circulatory system, we assumed
that the administered compound would be distributed rapidly
and uniformly in the hemolymph of the fly. The volume of the fly
hemolymph was estimated to be 0.5 l (see Materials and Meth-
ods), andwe assumed that clearancewas slow.With these assump-
tions, the highest concentration achieved for each compound can
be expressed as a multiple of the MIC. For example, for nisin, 1
MIC (10 g ml1) is equivalent to injection of 2.5 mg nisin kg
fly1, and these calculations can be found in Table 2 for all drugs.
Ampicillin was chosen as a control, as -lactams in general are
considered nontoxic to the host and can be administered at high
concentrations, in our case	1,000MIC. Ampicillin efficiently
promoted survival of 8325-4-infected flies (P  0.001) (Fig. 2A)
over a 70-h period, with no lethal effects on control animals (P
0.15), here defined as no difference in survival between flies in-
jected with VEH and those injected with both VEH and drug.
The two lantibiotics tested, i.e., NAI-107 and nisin, showed
good efficacy by effectively rescuing or delaying mortality of in-
fected flies over a 96-h period (Fig. 2B and C). Treatment with
NAI-107 at 3MIC did not show a positive effect on the survival
of 8325-4-infected flies.However, treatmentwithNAI-107 at 10
MIC rescued about 20 to 30% of flies (P 0.001). NAI-107 treat-
ment of control animals at 3MIC and 10MIChad no negative
effect on survival (P 0.62) (data not shown).We therefore tested
FIG 1 In vivo growth rates and killing of flies of the two bacterial isolates. (A) The in vivo growth rate of USA300 was 54 min, and that of strain 8325-4 was 104
min, demonstrating a difference in proliferation. Three flies were homogenized and serial dilutions were made in PBS before plating on S. aureus-selective MSA
to determine the number of CFU. (B) USA300 killed close to 100% of infected flies within 24 h, while isolate 8325-4 killed approximately 50% of flies within 24
h of infection (P 0.0001). Minor differences in the starting inoculums were observed (see Materials andMethods). Survival data are compiled results from all
in vivo kill rate experiments presented in Fig. 2 and 4.
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NAI-107 at 100MIC, and NAI-107 treatment at this concentra-
tion rescued more than 70% (P  0.0001) of the infected flies,
again without negative effects on survival of control animals (P
0.62) (Fig. 2B). Compared to NAI-107, nisin showed differences
in both efficacy and lethality in control animals.While nisin at 1
MICdelayed bacterial killing of flies (P 0.001), it produced signs
of lethal side effects in uninfected control animals injected with
nisin at 1MIC compared to VEH-injected control animals (P
0.018) (Fig. 2C). A higher concentration of nisin (3MIC) also
rescued a considerable fraction of infected animals (P  0.0002)
but showed pronounced detrimental effects on the survival of
control animals (P  0.006). These adverse effects were exacer-
bated with nisin at 10MIC, which resulted in the killing of 50%
of control animals injected with nisin alone (P 0.0001) and also
resulted in increased mortality of infected flies (Fig. 2C). There-
fore, nisin was not tested at 100MIC.
In contrast to NAI-107 and nisin, the GN-4 peptide, which
possesses good in vitro efficacy against S. aureus (Table 1) (41), did
not rescue infected flies at 1MIC and 3MIC (P	 0.05) (data
not shown). When applied at 10MIC, GN-4 showed no detri-
mental effects on survival of flies (Fig. 2D). However, the results
indicate that administration of this peptide to animals infected
with bacteria may reduce survival, because a larger number of the
animals treatedwith the peptide after infection died, although this
was not statistically significant. The GN-4 peptoid showed pro-
nounced negative effects on animal survival even at 1MIC (Fig.
2E) and was therefore not subjected to further testing. The GN-2
peptide had effects similar to those of the GN-4 peptide, and the
TABLE 1 MICs of compounds testeda
Compound Sequence (N terminus-C terminus) Stock solute mol wt
MIC (g ml1) MIC (M)
8325-4 USA300 8325-4 USA300
Peptides
Nisin H2O 3,354 10 4 2.98 1.19
NAI-107 DMSO 2,238 0.06 0.25 0.03 0.11
GN-2 RWKRWWRWI-CONH2 H2O 1,473 8 NA 5.43 NA
GN-4 RWKKWWRWL-CONH2 H2O 1,445 4 NA 2.77 NA
HHC-9 RWRRWKWWL-CONH2 H2O 1,473 4 NA 2.71 NA
HHC-36 KRWWKWWRR-CONH2 H2O 1,488 8 NA 5.38 NA
Peptoids
GN-2 Npm9 H-Nae-Ntrp-Nae-Nae-Ntrp-Ntrp-Nae-Ntrp-Nile-NH2 H2O 1,477 32 NA 22 NA
GN-2Ntrp5–8 H-Nlys-Nlys-Nlys-Nlys-Ntrp-Ntrp-Ntrp-Ntrp-NH2 H2O 1,443 16 NA 11 NA
GN-4 H-Nlys-Ntrp-Nlys-Nlys-Ntrp-Nlys-Ntrp-Nleu-NH2 H2O 1,443 64 NA 44 NA
Control antibiotics
Ampicillin H2O 349 0.01 NA 2.86 NA
Vancomycin H2O 1,449 NA 2 NA 1.38
a The molecular weights used for calculations of micromolar concentrations are given in the table. MICs of some compounds were not determined for both isolates (NA).
Sequences of nisin and NAI-107 are not included because they contain ring structures, making linear sequences misleading. Most compounds were dissolved in H2O. However, the
NAI-107 stock solution was prepared in 100% dimethyl sulfoxide (DMSO), but experimental in vitro and in vivo concentrations of DSMO did not exceed 0.5%, except in in vivo
experiments with NAI-107 at 100MIC (
6% DMSO). However, injection of 18.4 nl into a fly containing
500 nl fluid causes rapid dilution of the DMSO.
TABLE 2 Antibacterial peptide dosagesa
Compound
Target 1MIC (g l1)
in fly
amt injected for 1MIC
(g)
amt of compound injected
(mg kg fly1)
8325-4 USA300 8325-4 USA300 8325-4 USA300
Peptides
Nisin 0.01 0.004 0.005 0.002 6.25 2.5
NAI-107 0.00006 0.00025 0.00003 0.000125 0.04 0.16
GN-2 0.008 0.004 4
GN-4 0.004 0.002 2.5
HHC-9 0.004 0.002 2.5
HHC-36 0.008 0.004 5
Peptoids
GN-2 Npm9 0.032 0.016 20
GN-2 Ntrp5–8 0.016 0.008 10
GN-4 0.064 0.032 4
Control antibiotics
Ampicillin 0.00001 0.000005 0.01
Vancomycin 0.002 0.001 1.25
a All data presented are based on 1MICs of the compounds. The fly weight was 0.8 mg, and the fluid content of a fly was estimated to be 0.5 l (see Materials and Methods).
Thomsen et al.
5430 aac.asm.org September 2016 Volume 60 Number 9Antimicrobial Agents and Chemotherapy
 o
n
 January 6, 2017 by KB, Københavns Universitetsbibliotek
http://aac.asm
.org/
D
ow
nloaded from
 
two GN-2 peptoids clearly showed adverse effects on survival in
both control and infected animals (see Fig. S1 in the supplemental
material). Injection of the HHC-9 and HHC-36 peptides in the
absence of infection caused no obvious detrimental effects on sur-
vival. However, treatment with these peptides did not rescue in-
fected flies but instead caused a moderate decrease in survival of
infected animals that may indicate detrimental effects of peptides,
although the results are somewhat ambiguous.
We also noted an adverse behavioral response that may indi-
cate neurotoxicity in flies injected with high concentrations of
nisin, GN-2, andGN-4, alongwith the peptoids, but notNAI-107.
Animals reacted to injection with these compounds by being par-
tially paralyzed for up to 10 h postinjection (data not shown). This
paralysis was manifested not as complete immobilization but as
uncoordinated movements and an inability to walk or fly.
Treatment with nisin or NAI-107 reduces the immune re-
sponse of S. aureus-infectedDrosophila flies. To further test the
drug efficacy of the lantibiotics nisin and NAI-107 in vivo, we
examined the immune responses of both treated and nontreated
infected animals. We rationalized that infected animals treated
with these compounds would mount less of an immune response
provided that bacterial proliferation in the host was inhibited by
the compounds. To test this, we used flies infected with S. aureus
strain 8325-4. We administered NAI-107 at 100MIC, while ni-
sin, due to its detrimental side effect at high concentrations, was
injected only at 3MIC. Treatment of infected animals with am-
picillin (	1,000 MIC) was included for comparison with an
efficacious compound. Samples were taken in triplicate at 6 and
12 h postinfection, and uninfected flies served as controls. As a
measure of the immune response, we analyzed the expression of
the Drosomycin (Drs), Cecropin A1 (CecA1), and Attacin-B (AttB)
immunity genes, which have all been implicated in the immune
response ofDrosophila to infection byGram-positive bacteria (49,
50). In general, we observed that animals that received any formof
treatment had elevated transcription of immune response genes
(Fig. 3), most likely because any injection into the animals dam-
aged the tissue, thereby elevating the immune response. More-
over, it is highly plausible that injection of any protein-like struc-
ture will elicit some degree of immune response. Another general
observation was the presence of higher expression levels of im-
mune response genes in infected untreated animals than in ani-
mals treated with nisin and NAI-107.
FIG 2 In vivo efficacies of compounds against S. aureus 8325-4 in a Drosophila whole-animal model. The graphs show the effects of different peptides and
peptoids on survival of flies. (A) Ampicillin; (B) NAI-107; (C) nisin; (D) GN-4; (E) GN-4 peptoid. Flies were counted at 0, 3, 6, 12, 24, and 48 to 120 h. Flies were
injected with either vehicle (VEH) or isolate 8325-4 at time zero, with the indicated treatments given at 3 h (dotted lines). Flies were counted prior to injection
with compound. Compound concentrations are given as approximate concentrations in animals.
NAI-107 Efﬁciently Rescues Drosophila from USA300
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The responses of the three immune pathway genes differed.
Expression of Drs increased 30- to 180-fold within 6 h postinfec-
tion and remained at that level at 12 h postinfection (Fig. 3A).
Treatment with NAI-107 and nisin decreased Drs expression ap-
proximately 10-fold relative to that in nontreated infected flies at
12 h postinfection. Expression ofCecA1 followed the same pattern
as that observed for Drs, except that maximal induction was only
around 20-fold (Fig. 3B). The AttB expression level was different,
since gene expression was increased considerably in all flies in-
jected with peptides and irrespective of a concurrent S. aureus
infection (Fig. 3C). Because injection with VEH did not result in
the same fold increase ofAttB induction, we propose that theAttB
gene was initially induced by either the pathogen or the adminis-
tered peptides. The S. aureus infection further increased AttB ex-
pression, 	1,000-fold relative to that of the control, at 12 h
postinfection. Concurrent administration of nisin or NAI-107 re-
duced expression to the level observed for the peptides alone, or to
an even lower level. Some compounds, including nisin, have pre-
viously been associated with immunomodulatory actions in mice
(51). Consistent with this, our results indicate a moderate eleva-
tion in the expression ofDrs,CecA1, andAttB in flies injected with
nisin compared to VEH-injected control flies. However, whether
this is due to true immunomodulatory action or because of the
adverse side effects of nisin is unclear.
NAI-107 efficiently rescues flies from infection with MRSA
strain USA300. We proceeded to evaluate the in vivo efficacy of
lantibiotics relative to that of vancomycin in Drosophila flies in-
fected with USA300. Flies were treated with nisin at 1MIC, 3
MIC, and 10MIC. Although nisin did not rescue flies over the
duration of the experiment, it did delay mortality by doubling the
mean survival time (P 0.0001) at all concentrations tested (Fig.
4A). However, mortality was increased in the control group in-
jected with nisin at 10MIC relative to that of the VEH-injected
control group (P  0.0008). A single dose of NAI-107 at 100
MIC rescued 50 to 60% of USA300-infected animals over a 96-h
period (P  0.0001), equivalent to the survival found for vanco-
mycin treatment of animals at 10 MIC (P  0.94) (Fig. 4B).
Positive effects on the survival of USA300-infected animals were
also found at dosages of NAI-107 as low as 3MIC (P 0.0001).
Similarly to NAI-107, vancomycin showed no adverse effect on
survival of control animals at the concentrations tested here. The
effect on survival of infected animals was further corroborated by
FIG 3 Induction of immune response genes. Drosomycin (A), Cecropin A1
(B), and Attacin B (C) transcript levels were determined by qPCR. A nonin-
fected control group was used as a reference for normal expression, and the
average expression levels for this group were set at 1. Flies infected with S.
aureus 8325-4 were sampled for qPCR analysis at 6 and 12 h postinfection.
Drug treatmentwas performed at 3 h, and injection of vehicle (VEH) alonewas
used as a control. Due to the small sample size, statistical analysis was not
performed. Error bars indicate standard errors (n 3).
FIG 4 Efficacies of nisin and NAI-107 in vivo against S. aureus USA300. (A)
Nisin prolonged the life span of infected flies at all concentrations. (B) NAI-
107 rescued 50 to 60% of flies at 100MIC (P  0.001), similarly to vanco-
mycin at 10MIC. Antibiotics were injected at 3 h postinfection (dotted line).
(C) Bacterial titers in vivo in flies of the different treatment groups. Treatment
with antibiotics was given at 3 h postinfection, and bacterial titers at 3 h were
determined prior to treatment.
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the finding that in vivo treatment with vancomycin, nisin, or NAI-
107 clearly disrupted the proliferation of bacteria inside the ani-
mals (Fig. 4C). By 24 h, the bacterial load for animals treated with
NAI-107 dropped below the count seen after 3 h, the time atwhich
the animals were treated. Our data also indicate that, by 24 h,
NAI-107 was slightly more effective than vancomycin based on
median values, although this was not statistically significant.
However, treatment with NAI-107 or vancomycin significantly
reduced the bacterial load in flies compared to that with nisin
treatment after 24 h (P  0.0001). Taken together, these results
demonstrate that NAI-107 delays killing ofDrosophila by systemic
USA300 infections with an efficiency similar to that of vancomy-
cin and with no changes to survival of control animals. This high-
lights the potential of NAI-107 as a candidate for systemically
administered application.
DISCUSSION
We used Drosophila as an infection model for testing the efficacy
and adverse effects of peptides and peptoids.We examined several
cationic antibacterial peptides and peptoids previously reported
to have either in vitro or in vivo efficacy against S. aureus. Further-
more, two lantibiotics, nisin and NAI-107, were included. We
found that both lantibiotics can delay or even rescue lethal injec-
tions with wild-type S. aureus 8325-4 and, more importantly, also
those with the MRSA USA300 isolate.
We generally demonstrated that most of the amphipathic pep-
tides and peptoids previously tested in vitro and/or in vivo against
both Gram-negative and Gram-positive bacteria (41) had no pos-
itive effect on the survival of S. aureus-infected flies. These pep-
tides are generally believed to work through electrostatic interac-
tions with the negatively charged bacterial membrane (41, 42, 52,
53) and consequent pore formation, thereby disrupting the integ-
rity of the bacterial membrane(s). This mechanism of action
should exclude interactionwith themore zwitterionicmembranes
of eukaryotic cells (52). The peptoids proved to bemost detrimen-
tal to the flies, but the effect might simply be explained by the high
concentrations of these molecules, as they had to be injected at
high concentrations to reach the samemultiple of theMIC as that
for the corresponding peptide. Previous studies described that
peptoids are hemolytic and cytotoxic in vitro at concentrations
ranging from 100 to 170 g ml1 (45), yet our findings indicate
that these compounds may have adverse effects in vivo even at
lower concentrations (1 MIC [64 g ml1] for the GN-4 pep-
toid and 3 MIC [48 g ml1] for the GN-2 Ntrp5–8 peptoid).
For the GN peptides, previous studies have shown that they are
cytotoxic at levels of approximately 40 g ml1 (42, 45), which is
largely consistent with most of our findings for comparing in-
jected concentrations with the in vitro data. Although our data
cannot exclude the possibility that the GN peptides and peptoids
may be effective inmammalianmodels, theDrosophila in vivodata
presented here do not support their use for whole-animal infec-
tions.
The cationic amphipathic HHC-9 and HHC-36 peptides had
either no or a marked negative effect on the survival of infected
flies. This contrasts with previous data showing that HHC-36 had
low in vivo efficacy against S. aureus in a well-established mouse
intraperitoneal (i.p.) model (44). However, Cherkasov et al. (44)
tested the cytotoxicity of HHC-36 by hemolysis assay only, which
makes it difficult to compare with our in vivo data. Furthermore,
we observed that nisin reduced animal survival even at relatively
low concentrations in our model. Previous in vivo findings from
rat studies that utilized administration through oral dosing did
not observe adverse effects of nisin (54). However, this might be
explained by the fact that our study utilized injection into the
circulatory system of whole animals, while rats were exposed
through oral administration, which inevitably changes the bio-
availability and potential adverse effects of a compound (55). Ni-
sin has also been shown to be degraded by proteases in the diges-
tive system (56). Perhaps nisin, because of its poor bioavailability
and fast degradation (57), may be modified chemically to address
these issues (19, 58), and in this context it would be important to
know more about its potential adverse effects.
Although we expected the HHC compounds and nisin to be
able to clear or delay infection in Drosophila, our results indicate
that their injection into the circulation at high concentrations has
negative effects on flies. The number of in vivo experiments per-
formed previously for the analysis of systemic administration of
HHC peptides and nisin is limited, and Drosophila has not been
established as a model of infection directly comparable to other
mammalian systems. Therefore, it is difficult to explain the ob-
served differences. However, we believe that there is one impor-
tant difference that should be considered between the in vivo stud-
ies performed with these peptides in mice and our work on
Drosophila. InDrosophila, bacteria and peptides are delivered sys-
temically into the circulation, while both are injected into the
body cavity in the i.p. mouse model previously used to test the
HHCpeptides in vivo (44). It is not clear whether the peptides and
bacteria enter the circulation in the i.p. mouse model, which may
minimize adverse effects of these compounds and therefore not be
predictive of negative effects in the whole animal. We argue that
injection of peptides and bacteria into the open circulatory system
of a fly provides access to more diverse tissues, which may be an
advantage when it comes to identifying compounds withminimal
toxicity and high efficacy during early phases of drug develop-
ment. The open circulatory system of the flymay alsomake the fly
model hypersensitive to adverse effects and explain the differences
observed. We contemplate that hypersensitivity in the Drosophila
model might actually be beneficial in early development for iden-
tification of candidates with good efficacy and a low risk of toxicity
that will succeed during later stages of development. Late-stage
failure in clinical trials has previously been reported as a problem
in the development of peptide antibiotics (59). Although the po-
tential for systemic application of nisin and most of the other
molecules seems limited based on our findings, our data also re-
inforce the notion that nisin and these other molecules may have
other therapeutic applications in clinical settings. These antibac-
terials may be developed further and optimized for topical usage,
as was the case for the systemically toxic peptide antibiotic baci-
tracin, which has been highly successful in topical ointments (60,
61). However, it is important that adverse effects observed inDro-
sophila should not necessarily be considered a definite rejection of
compounds, since these results may be used for further structure
relationship studies and development of better compounds.
Therefore, further studies are needed to address the intricate in-
teractions of nisin with eukaryotic cell systems, especially since
our data indicate possible adverse effects to the nervous system.
Although the bacterial targets of nisin have been characterized
(22, 62, 63), the interplay of nisin with other molecules of eukary-
otic cells remains poorly understood.
To the best of our knowledge, Drosophila has not previously
NAI-107 Efﬁciently Rescues Drosophila from USA300
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been used for testing of antibacterial peptide efficacy and toxicity.
Drosophila does not allow for high-throughput screening of large
drug libraries by injection, as this procedure is relatively labor-
intensive compared to drug screening methodologies developed
with the worm Caenorhabditis elegans (64). However, in contrast
to C. elegans, our Drosophila model has the advantage that com-
pounds that may be degraded during oral uptake can be injected
into the circulation, which makes it suitable for testing of lead
compounds. Therefore, Drosophila may prove important as an
initial whole-animal model for identifying lead compounds with
high efficacy and low toxicity, as classical toxicity screens usually
involve hemolysis- and metabolic cell-based assays that do not
recapitulate the complexity of a whole-animal system. To deter-
mine the usefulness of the Drosophila model of infection and
whether it is hypersensitive, it will be important to determine its
comparability to mammalian models and to develop strategies to
measure actual drug concentrations in the fly hemolymph
(blood). Based on our data presented here and the fact that Dro-
sophilahas proved to be a usefulmodel for identifying other drugs,
including anticancer therapeutics that are now used in the clinic
(25, 65, 66), we believe that it has the potential to be an important
model for antibacterial drug testing.
Additionally, our data enforce the notion that the lantibiotics
remain of greatest interest for development of new therapeutics.
As one of the best-studied lantibiotics (19), nisin recently gained
new interest as a therapeutic because it was proven to be effective
against MRSA (67, 68; this study), but it may require further tox-
icological studies. The newly discovered lantibiotic NAI-107 is
currently undergoing preclinical studies, and it has already proven
effective in vivo against MDR S. aureus (39, 69). NAI-107 delayed
death due to infection at doses of around 10MIC inDrosophila.
Higher doses of NAI-107 resulted in remarkable in vivo efficacy,
with no adverse effects. This is consistent with the previous find-
ing that the effects of NAI-107 are concentration dependent (69).
Nisin was clearly less potent than NAI-107 in vivo, although both
compounds bind to lipid II (70) and rapidly kill bacteria.
In conclusion, we provide evidence for the use ofDrosophila as
a model for in vivo efficacy testing of antimicrobial peptides.
Among the compounds we tested, the lantibiotic NAI-107 was
superior to nisin but equivalent to vancomycin. Our data clearly
show that infected flies can be rescued by treatment with certain
antibacterial peptides. Importantly, the antibiotics (ampicillin
and vancomycin) that are efficacious in the clinic are also effica-
cious in ourmodel and do not produce any signs of adverse health
effects. Furthermore, NAI-107, which shows efficacy in both i.p.
and intravenous mammalian infection models (39, 69), shows
high efficacy without adverse effects in our model. These results
highlight that the Drosophila model is useful for evaluating the
whole-animal efficacy of antibacterials. The Drosophila model
presented here provides a cost-effective whole-animal system for
development of lead antibacterial compounds with low toxicity
and high efficacy.
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